What Igenomix does

Igenomix is a reproductive genetics company founded in 2009 in Valencia, Spain, and operating since 2021 as a core subsidiary of Sweden-listed Vitrolife Group. It provides specialized preimplantation, endometrial, and carrier genetic testing services for the IVF market, addressing repeated implantation failure, recurrent pregnancy loss, chromosomal aneuploidies, structural rearrangements, monogenic disease transmission, male-factor infertility, and chronic endometritis. Its product portfolio spans PGT-A, PGT-A Plus, PGT-M, PGT-SR, PGT-SR Plus, EMBRACE (non-invasive culture-medium testing), MitoScore, ERA, EMMA, ALICE, the integrated EndomeTRIO platform, the CGT family (Bank, Plus, Flex, Exome), POC, and SAT.

The technology stack is anchored in Next Generation Sequencing combined with proprietary AI algorithms. The Smart PGT-A model is trained on more than 100,000 embryo samples, while the ERA calculator is trained on over 200,000 endometrial biopsies and linked clinical transfer outcomes to identify patient-specific implantation windows; ERA is patent-protected (PCT/ES2009/000386) with additional patents pending in endometrial transformation methods and leiomyoma diagnostics. Bioinformatics pipelines operate as automated process-control layers across the full test menu.

Commercially, Igenomix runs a sales-led B2B laboratory services model. Revenue is generated by selling genetic tests to 3,000+ fertility clinics and reproductive medicine specialists worldwide, with samples collected at the clinic and analyzed in Igenomix's international network of 20-23 laboratories spanning the Americas, Europe, Asia, and the Middle East. Pricing is quote-based and not publicly disclosed; tests are billed per service, and customer acquisition leans on clinical evidence (the only endometrial receptivity test backed by a randomized controlled trial, per company materials), conference presence, and referral relationships with reproductive medicine specialists. The publicly profiled Latam website represents a regional commercial unit headquartered in Chacarilla, Peru, with offices in Mexico City, Bogotá, Lima, Buenos Aires, and Santiago, marketing the same Vitrolife Group-aligned service catalog to Latin American clinics and patients.

Name

Igenomix

Legal name

Igenomix S.L.

Website

https://latam.igenomix.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Igenomix is a B2B reproductive genetics laboratory offering preimplantation, endometrial, and carrier genetic tests (PGT-A, PGT-M, PGT-SR, ERA, EMMA, ALICE, CGT, EMBRACE) to 3,000+ fertility clinics worldwide, operated as a Vitrolife Group subsidiary across a network of 20+ international laboratories.

Ownership category

akta.pro rank

Product category

Reproductive Genetic Testing Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)

akta.pro secondary industries

Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Genetic & Prenatal Testing Laboratories (HLAFAMAH), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Reproductive Endocrinology & Infertility (IVF/Fertility) (HLAKAJAC)

Keywords

• Reproductive genetic testing
• Preimplantation genetic testing
• Endometrial receptivity analysis
• Carrier genetic screening
• Fertility diagnostics

Headquarters

HQ city

Chacarilla

HQ country

Peru

HQ region

Latin America

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Genetic Testing Services: Igenomix generates revenue through providing genetic testing services to fertility clinics and reproductive medicine specialists. Tests include PGT-A, PGT-M, PGT-SR, ERA, EMMA, ALICE, CGT, and comprehensive panels like EndomeTRIO. Services are provided to healthcare providers who order tests for their patients undergoing fertility treatments.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Igenomix is a reproductive genetics laboratory that sells genetic testing services to fertility clinics and reproductive medicine specialists. Its portfolio spans preimplantation testing (PGT-A, PGT-M, PGT-SR), endometrial receptivity and microbiome analyses (ERA, EMMA, ALICE, EndomeTRIO), and preconception and miscarriage diagnostics (CGT, POC, SAT, EMBRACE, MitoScore). Tests are performed using Next Generation Sequencing combined with proprietary AI algorithms trained on the industry's largest reproductive genetics datasets, with results delivered back to ordering clinics to guide IVF treatment decisions.

Product overview

Igenomix is a reproductive genetics laboratory offering a comprehensive portfolio of genetic testing services organized around three pillars: Preimplantation Testing (PGT-A, PGT-A Plus, PGT-M, PGT-SR, PGT-SR Plus, EMBRACE, MitoScore), Endometrial Testing (ERA, EMMA, ALICE, EndomeTRIO), and Carrier/Other Testing (CGT variants, POC, SAT). The flagship EndomeTRIO platform combines ERA, EMMA, and ALICE into a single biopsy for comprehensive endometrial health assessment. PGT-A and PGT-A Plus utilize proprietary NGS technology with AI-driven algorithms for embryo selection. CGT offers multiple tiers (Bank, Plus, Flex, Exome) for preconception carrier screening based on whole exome sequencing. All tests are performed in Igenomix's international laboratory network spanning 20+ countries.

Differentiator

Problem solved

Functional benefit

Brands

• ERA (Endometrial Receptivity Analysis): Patent-protected diagnostic test that evaluates endometrial receptivity to identify the implantation window for personalized embryo transfer.
• EMMA (Endometrial Microbiome Metagenomic Analysis)
• ALICE (Analysis of Infectious Chronic Endometritis)
• PGT-A (Preimplantation Genetic Testing for Aneuploidies)
• PGT-M (Preimplantation Genetic Testing for Monogenic Diseases)
• PGT-SR (Preimplantation Genetic Testing for Structural Rearrangements)
• EMBRACE (Embryo Analysis of Culture Environment)
• CGT (Carrier Genetic Test)
• POC (Products of Conception)
• SAT (Sperm Aneuploidy Test)
• EndomeTRIO

Products and services

• PGT-A (Preimplantation Genetic Testing for Aneuploidies) Genetic test that analyzes all 24 chromosomes in embryos to identify and select chromosomally normal embryos for transfer during IVF treatment, increasing pregnancy rates and reducing miscarriage risk. Built on NGS technology and the Smart PGT-A AI algorithm trained on 100,000+ embryo samples.
• PGT-A Plus Enhanced PGT-A combining NGS with SNP (Single Nucleotide Polymorphism) analysis for superior precision, ploidy detection (haploid/triploid) and embryo traceability controls without requiring parental samples.
• PGT-M (Preimplantation Genetic Testing for Monogenic Diseases) Preimplantation genetic diagnosis analyzing embryo DNA to identify and select disease-free embryos for couples at risk of transmitting monogenic hereditary diseases such as cystic fibrosis or spinal muscular atrophy, with 98% accuracy and more than 500 monogenic diseases covered.
• PGT-SR (Preimplantation Genetic Testing for Structural Rearrangements) Genetic test detecting chromosomal imbalances resulting from parental structural rearrangements such as translocations and inversions using customized NGS with a proprietary AI algorithm, combined with aneuploidy screening at 98% accuracy for imbalances ≥6MB.
• PGT-SR Plus Advanced PGT-SR incorporating both NGS and SNP analysis with ploidy detection, embryo cohort verification and contamination detection for enhanced precision.
• ERA (Endometrial Receptivity Analysis) Patent-protected diagnostic test that evaluates endometrial receptivity by analyzing expression of 248 genes to identify each patient's unique implantation window for personalized embryo transfer, supported by the only endometrial receptivity test backed by a randomized controlled trial.
• EMMA (Endometrial Microbiome Metagenomic Analysis) Test analyzing endometrial microbiome using NGS to determine levels of Lactobacillus and dysbiotic bacteria, recommending appropriate probiotic or antibiotic treatment to improve reproductive prognosis.
• ALICE (Analysis of Infectious Chronic Endometritis) Diagnostic test detecting pathogenic bacteria that cause chronic endometritis using microbiological methods (cultivable and non-cultivable pathogen identification), recommending appropriate antibiotic and probiotic treatment to improve reproductive outcomes.
• EndomeTRIO Comprehensive endometrial health analysis combining ERA, EMMA and ALICE tests in a single biopsy, providing complete assessment of receptivity, microbiome and infectious endometritis from one sample.
• CGT (Carrier Genetic Test) Preconception genetic screening test based on whole exome sequencing that detects carrier status across hundreds to thousands of recessive genetic diseases to assess the risk of having an affected child. Offered in multiple panel tiers (CGT Bank for donors, CGT Plus with 455 autosomal recessive plus 64 X-linked genes, CGT Flex customizable up to 10 genes or with hereditary cancer screening, and CGT Exome for full-exome coverage).
• POC (Products of Conception) Genetic analysis of pregnancy loss tissue using NGS to determine whether a miscarriage was caused by chromosomal abnormalities (86.4% fetal origin results), providing information to guide future reproductive planning.
• SAT (Sperm Aneuploidy Test) Diagnostic test analyzing 2,000 spermatozoa for chromosomal abnormalities related to recurrent pregnancy loss and failed IVF cycles, evaluating chromosomes 13, 18, 21, X and Y for male infertility diagnosis.
• EMBRACE (Embryo Analysis of Culture Environment) Non-invasive preimplantation genetic test analyzing cell-free embryonic DNA in embryo culture medium to assess chromosomal status without embryo biopsy, with a 78.2% concordance rate versus invasive biopsy and broader patient access.
• MitoScore Biological marker quantifying mitochondrial DNA in embryos to predict implantation potential and provide additional criteria for embryo transfer prioritization alongside PGT-A.

Quantifiable outcome

• Doubles IVF success rates when treatment is personalized with genetic testing support (from 30-40% to ~80% birth rate per cycle)
• +7 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature10 records

Partnerships

One partnership is on record.

• Vitrolife GroupcoreStrategic or Co-development Partner · 1 January 2021In 2021, Vitrolife acquired Igenomix, creating Vitrolife Group - a global leader in reproductive health. The combination integrates Igenomix's genetic testing portfolio with Vitrolife's IVF device portfolio, supporting clinics and patients throughout the fertility journey.

Scale indicators13 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Natera: Natera offers reproductive genetic testing including Empower (PGT) and Vistara, directly competing with Igenomix's PGT-A, PGT-M, and carrier screening services for the same fertility clinic customers.
• CooperSurgical (CooperGenomics): CooperSurgical's PGT and reproductive genetics services (historically CooperGenomics) directly overlap with Igenomix's preimplantation testing portfolio and target the same IVF clinic channel globally.
• Myriad Genetics: Myriad provides carrier screening (Foresight) and hereditary cancer testing, overlapping with Igenomix's CGT carrier screening product and broader reproductive genetics offering.
• Invitae: Invitae offers broad genetic testing including carrier screening and reproductive health panels, competing with Igenomix's CGT and other carrier/preconception testing services for clinic and patient customers.
• Sema4: Sema4 (now GeneDx for reproductive health) provides NGS-based reproductive and women's health genetic testing, competing with Igenomix's PGT and carrier screening portfolio for clinics and patients.

Emerging players

• Genomic Prediction: Genomic Prediction offers advanced PGT including polygenic risk screening for embryos, representing an emerging technology frontier that overlaps with Igenomix's PGT-A Plus and could compete on next-generation embryo selection.
• Centogene: Centogene specializes in rare disease and reproductive carrier screening using whole exome sequencing, offering CGT-like services that overlap with Igenomix's CGT Exome and carrier testing products.
• Baylor Genetics: Baylor Genetics provides clinical genetic and genomic testing including reproductive and prenatal diagnostics, competing with several of Igenomix's specialty genetic testing services for specialist clinicians.

Broad incumbents

• Labcorp: Labcorp operates a global clinical laboratory network offering reproductive and genetic testing services, providing scale-based competition to Igenomix especially in North America through its broad diagnostics portfolio.
• Quest Diagnostics: Quest Diagnostics provides women's health and reproductive genetic testing through its broad clinical lab network, competing with Igenomix in carrier screening and reproductive diagnostics for physician customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/igenomix-latam

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Igenomix